Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication
Completed · Not applicable
Conditions studied: Adherence, Medication
In brief
Boston Medical Center provides care to cancer patients on oral cancer medications through the use of Boston Medical Center Specialty Pharmacy (BMC SP). The use of oral medications in cancer treatments is relatively new and unfortunately, very little is known about adherence in cancer patients. This study will evaluate the influence of a pharmacist-driven medication management program on adherence and persistence rates. Boston Medical Center's Specialty Pharmacy Adherence Program (B-SPAP), will utilize a high-touch counseling model involving clinical pharmacist that will focus on educating patients about their oral cancer treatments. The program will require face-to-face counseling with a pharmacist, through the use of a proven patient teaching tool, prior to initiating treatment with oral oncolytic treatments and, periodically thereafter, based on protocol. This study will help improve our understanding of the role of the pharmacist in cancer patients. In addition, the study will help identify independent factors that may contribute or impact adherence. The outcomes of this program will be compared to a historical control group of patients that have already received treatment for their cancer through the BMC Specialty Pharmacy.
Key facts
- Study ID
- NCT03104114
- Run by
- Boston Medical Center
- People needed
- 216
- Starts
- 2017-05-02
- Expected to finish
- 2019-02-15
- Last updated by the study team
- 2019-08-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Treatment with 1 or more oral oncology agents. Oral oncology agent defined as medication taken mouth with the purpose to treat a patient's cancer
- Treatment dispensed through the BMC Specialty Pharmacy
- Age>18 years
- Life expectancy >6 months
- Patients must have ability to give written consent, or, must have a legally authorized representative
You may not qualify if…
- Treatment indicated for neoadjuvant, adjuvant, peri-operative treatment
- Concurrent radiation treatment
- Patients that are unable to have oral oncology agents dispense through BMC Specialty Pharmacy
- Historical Control:
- 2 controls:1 intervention match
- Matched to a patient in intervention group based on drug type
Where it is running
- Boston Medical Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.